UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 30, 2005

 

 

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

128 Sidney Street, Cambridge, MA       02139

(Address of principal executive offices)   (Zip Code)

 

 

Registrant’s telephone number, including area code: (617) 995-2500

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

        o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

        o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

        o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

        o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

ITEM 8.01 — OTHER EVENTS

 

On March 31, 2005, ImmunoGen, Inc. issued a press release to announce that it has submitted to the US Food and Drug Administration (FDA) an Investigational New Drug application (IND) for its wholly owned huC242-DM4 targeted anticancer therapeutic.  HuC242-DM4, a Tumor-Activated Prodrug (TAP) compound, is in development by the Company for the treatment of CanAg-expressing cancers, such as gastrointestinal and non-small-cell lung cancers.  A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

 

 

 

 

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

 

Exhibit No.		Exhibit
99.1		Press Release of ImmunoGen, Inc. dated March 31, 2005

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

		ImmunoGen, Inc.
		(Registrant)
Date: March 31, 2005		/s/ Karleen M. Oberton
		Karleen M. Oberton
		Senior Corporate Controller
		(Principal Accounting and Financial Officer)

 

 

 

3